Journal article · 2026 · Open access
Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound
Journal of Clinical Investigation, 136(6) · Published 29 January 2026 · DOI 10.1172/jci198294
In brief
“Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound” is a 2026 journal article by Robert Were Omange and 29 co-authors, published in Journal of Clinical Investigation. OpenAlex counts 7 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Journal of Clinical Investigation.
- Citations
- 7
- Most cited in
- 2026 (6)
- Field-weighted impact
- 7.97
- References
- 66
- Authors
- 30
Abstract
HIV/SIV-specific CD8+ T cell responses are typically unable to control viral rebound following antiretroviral therapy (ART) interruption (ATI). To investigate whether enhancing the magnitude and activation of SIV-specific CD8+ T cells at the time of ATI can improve the immune interception of reactivating SIV infections, we vaccinated SIVmac239-infected rhesus macaques (RMs) on ART, boosting immediately prior to ATI, with a nucleoside-unmodified mRNA vaccine expressing SIVmac239 Gag (mRNA/SIVgag) alone or in combination with Nef (mRNA/SIVnef) and Pol (mRNA/SIVpol). The mRNA/SIVgag vaccine was effective in boosting Gag-specific CD8+ T cells in blood and lymphoid tissues. Following ATI, the mRNA/SIVgag vaccine group showed a significant delay in time to measurable viral rebound compared with controls and manifested lower plasma viral loads (PVLs) for up to 6 weeks after rebound. Similarly, RMs that received mRNA/SIVgag, mRNA/SIVnef, and mRNA/SIVpol also manifested a delay in SIV rebound compared with controls, suggesting that boosting SIV-specific CD8+ T cells during ATI can enhance early immune targeting of reactivating SIV infections. However, viral control was not sustained long term as PVLs were similar across vaccinees and controls by 24 weeks after rebound, highlighting the need for adjunctive therapies to improve the durability of virologic control elicited by CD8+ T cell-targeting vaccines.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Omange, R. W., Varco-Merth, B. D., Fadeyi, O., Marenco, A., Takata, H., Duell, D. M., Goodwin, W. D., Armitage, P., Fennessey, C. M., Köse, E., Immonen, T. T., Kosmider, E., Bosche, W. J., Fast, R. L., Homick, C., Oswald, K. A., Shoemaker, R. S., Bochart, R. M., MacAllister, R., . . . Okoye, A. A. (2026). Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound. Journal of Clinical Investigation, 136(6). https://doi.org/10.1172/jci198294
MLA 9
Omange, Robert Were, et al. “Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.” Journal of Clinical Investigation, vol. 136, no. 6, 2026. https://doi.org/10.1172/jci198294.
Chicago
Omange, Robert Were, Benjamin D. Varco-Merth, O. Fadeyi, Alejandra Marenco, Hiroshi Takata, Derick M. Duell, William Douglass Goodwin, et al. 2026. “Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.” Journal of Clinical Investigation 136 (6). https://doi.org/10.1172/jci198294.
Harvard
Omange, R. W. et al. (2026) ‘Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound’, Journal of Clinical Investigation, 136(6). doi:10.1172/jci198294.
IEEE
R. W. Omange et al., “Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound,” Journal of Clinical Investigation, vol. 136, no. 6, 2026, doi: 10.1172/jci198294.
BibTeX
@article{omange2026boosting,
title = {{Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound}},
author = {Omange, Robert Were and Varco-Merth, Benjamin D. and Fadeyi, O. and Marenco, Alejandra and Takata, Hiroshi and Duell, Derick M. and Goodwin, William Douglass and Armitage, Paula and Fennessey, Christine M. and Köse, Emek and Immonen, Taina T. and Kosmider, Ewelina and Bosche, William J. and Fast, Randy L. and Homick, Christopher and Oswald, Kelli A. and Shoemaker, Rebecca S. and Bochart, Rachele M. and MacAllister, Rhonda and Labriola, Caralyn S. and Smedley, Jeremy V and Axthelm, Michael K. and Edlefsen, Paul T. and Keele, Brandon F. and Lifson, Jeffrey D. and Gergen, Janina and Petsch, Benjamin and Rauch, Susanne and Picker, Louis J. and Okoye, Afam A.},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {6},
doi = {10.1172/jci198294},
url = {https://doi.org/10.1172/jci198294}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- SIVmac239
- antiretroviral therapy interruption
- viral rebound
- mRNA vaccines
- SIV Gag
- rhesus monkeys
- immune boosting
- virus control
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Omange, R. W., Varco-Merth, B. D., Fadeyi, O., Marenco, A., Takata, H., Duell, D. M., Goodwin, W. D., Armitage, P., Fennessey, C. M., Köse, E., Immonen, T. T., Kosmider, E., Bosche, W. J., Fast, R. L., Homick, C., Oswald, K. A., Shoemaker, R. S., Bochart, R. M., MacAllister, R., . . . Okoye, A. A. (2026). Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound. Journal of Clinical Investigation, 136(6). https://doi.org/10.1172/jci198294
How many times has this paper been cited?
7 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Clinical Investigation: sign in and open the PDF from this page.
Who wrote this paper?
Robert Were Omange, Benjamin D. Varco-Merth, O. Fadeyi, Alejandra Marenco, Hiroshi Takata, Derick M. Duell, William Douglass Goodwin, Paula Armitage, Christine M. Fennessey, Emek Köse, Taina T. Immonen, Ewelina Kosmider and 18 more.
What is the DOI of this paper?
10.1172/jci198294, permanently at https://doi.org/10.1172/jci198294. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.